[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hcc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hcc":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,46,75,125,160,181,225,247,269,297,317,340,363,384,404,424,444,461,485,517,539,561,589,611,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100530236","ceus-vs-amri-for-hcc-detection-in-patients-with-indeterminate-liver-nodules-100530236",false,"NCT06184152","CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules","Contrast Ultrasound vs. Abbreviated MRI for Detection of HCC in Patients With Indeterminate Liver Nodules","Inclusion Criteria:\n\n* Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.\n* Adults 18 years old and above\n\nExclusion Criteria:\n\n* Patients post liver transplantation\n* Patients with concurrent or prior HCC (LR-5 or biopsy proven)\n* other liver cancer including cholangiocarcinoma\n* Patients with any active extra-hepatic malignancy\n* Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit\n* Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study will be conducted at the following locations:\n\n1. UT Southwestern Medical Center\n2. Parkland Health and Hospital System\n3. University of Michigan\n\nInvestigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.",[27,28],"HCC","Hepatocellular Carcinoma",[30,31,32],"LR3","LR4","HCC Surveillance","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2023-11-28",{"date":41,"type":21},"2028-11-28",{"name":43,"class":44},"University of Texas Southwestern Medical Center","OTHER",2,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100398793","phase-2-cabozantinib-combined-with-ipilimumabnivolumab-and-tace-in-patients-with-hepatocellular-carcinoma-100398793","NCT04472767","Cabozantinib Combined With Ipilimumab\u002FNivolumab and TACE in Patients With Hepatocellular Carcinoma","Phase 2 Study of Cabozantinib Combined With Ipilimumab\u002FNivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment","Inclusion Criteria:\n\n* Histologic or radiographic diagnosis of hepatocellular carcinoma\n* At least one lesion amenable to TACE treatment\n* Child-Pugh A-B7 (B7 based on Albumin allowed)\n* Not a candidate for resection or transplantation\n* Age ≥ 18 years.\n* Performance status: ECOG performance status ≤2\n* Must have at least one measurable lesion (either untreated or progressed after previous locoregional treatment)\n* Adequate organ and marrow function as defined below:\n\n  1. Leukocytes ≥ 2,000\u002FmcL\n  2. absolute neutrophil count ≥ 1000\u002FmcL\n  3. platelets ≥ 60,000\u002Fmcl\n  4. total bilirubin within normal institutional limits\n  5. AST(SGOT)\u002FALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present\n  6. creatinine \\\u003C1.5ULN\n  7. hemoglobin ≥ 8 g\u002FdL\n  8. Serum albumin ≥ 2.8 g\u002FdL\n  9. Urine protein\u002Fcreatinine ration (UPCR) ≤ 1 mg\u002Fmg\n* The effects of cabozantinib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nBased on its mechanism of action, ipilimumab can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception during treatment with ipilimumab and for 3 months following the last dose of ipilimumab.\n\nBased on its mechanism of action, nivolumab can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception during treatment with nivolumab and for 5 months following the last dose of nivolumab.\n\n1\\. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n1. Has not undergone a hysterectomy or bilateral oophorectomy; or\n2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\n   * Life expectancy of greater than 3 months\n   * Ability to swallow tablets\n   * Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Any type of previous systemic anti-cancer treatment\n* All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline\n* Any locoregional treatment for HCC within 3 months\n* Vp4 or Vp3 portal vein thrombus\n* Extrahepatic disease\n* Patients may not be receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, cabozantinib or other agents used in study.\n* Concomitant anticoagulation with coumarin agents (eg, warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitors (e.g., rivaroxaban), or platelet inhibitors (eg, clopidogrel). Allowed anticoagulants are the following:\n\n  1. Prophylactic use of low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose low molecular weight heparins (LMWH).\n  2. Therapeutic doses of LMWH in subjects with a screening platelet count \\> 100,000\u002FμL, without known brain metastases, and who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n* The subject has prothrombin time (PT)\u002FINR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 28 days before the first dose of study treatment.\n* Uncontrolled intercurrent illness including, but not limited to, the following conditions:\n\n  1. ongoing or active infection\n  2. symptomatic congestive heart failure\n  3. uncontrolled hypertension defined as sustained blood pressure (BP) \\> 150 mm Hg systolic or \\> 100 mm Hg diastolic despite optimal antihypertensive treatment\n  4. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before first dose\n  5. unstable angina pectoris\n  6. cardiac arrhythmia\n  7. evidence of tumor invading GI tract, active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n  8. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.\n\n     Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.\n  9. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose.\n  10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n  11. Lesions invading any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible.\n  12. Other clinically significant disorders that would preclude safe study participation:\n\n      1. Serious non-healing wound\u002Fulcer\u002Fbone fracture\n      2. Uncompensated\u002Fsymptomatic hypothyroidism\n      3. Moderate to severe hepatic impairment (Child-Pugh B or C)\n  13. psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n* Prior treatment with cabozantinib\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment.\n\nCorrected QT (QTc) = QT \u002F ∛RR\n\nQT: duration of QT interval RR: duration of RR interval\n\nNote: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n* History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ and not treated with systemic therapy.\n* Inability to comply with study and follow-up procedures as judged by the Investigator\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants\n* Has fibrolamellar HCC\n* Has received prior cytotoxic, biologic or other systemic anticancer therapy including investigational agents within 4 weeks prior to randomization.\n* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Has received a live vaccine within 30 days prior to the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n* Has severe hypersensitivity (Grade ≥ 3) to nivolumab or cabozantinib and\u002For any of their excipients.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a known history of human immunodeficiency virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n* Has a known history of active tuberculosis (TB; Bacillus tuberculosis).\n* Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":54,"type":21},35,[56],"PHASE2","This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab\u002Fnivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.",[28,27],[28,27,60,61,62,63,64],"Cabozantinib","Ipilimumab","Nivolumab","TACE","transarterial chemoembolization","2026-06-29",{"date":67,"type":37},"2026-07-01",{"date":69,"type":37},"2020-08-07",{"date":71,"type":21},"2027-09-01",{"name":73,"class":44},"University of California, Irvine",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":74},"100604152","phase-2-y-90-treatment-response-using-transarterial-radioembolization-100604152","NCT07145801","Y-90 Treatment Response Using Transarterial Radioembolization","Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response","TARE","Inclusion Criteria:\n\n* Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.\n* Be at least 18 years of age.\n* Be medically stable.\n* If a female of child-bearing age, must have a negative pregnancy test.\n* Have signed Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.\n* Patients with known sensitivities to the components of Lumason.\n* Patients with known sensitivities to the components of Sonazoid.",{"count":84,"type":21},30,[56],"This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing cause of cancer mortality in the United States. TARE is recommended for 15-25% of HCC patients. Treatment response is generally evaluated using contrast-enhanced CT or MRI 1-2 months and 4-6 months post-TARE. Although TARE is an effective therapy, assessment of treatment response using CT\u002FMRI is challenging because CT\u002FMRI frequently diagnoses tumor response as equivocal or non-progressing for up to 6 months post-TARE based on LI-RADS criteria. This delay in diagnosing tumor viability subsequently delays needed retreatment and can even serve as a barrier to transplantation. Our prior work in HCC locoregional therapy has shown CEUS provides improved sensitivity in detecting viable tumor following transarterial chemoembolization relative to traditional CT\u002FMRI. Therefore, the investigators propose to evaluate both qualitative and quantitative CEUS as a tool for evaluating HCC post-TARE at similar time points of clinically recommended cross-sectional imaging, while also investigating the role of Kupffer phase imaging.\n\nThe investigators plan to enroll a total of 30 patients scheduled for TARE of a treatment naïve HCC over an 18-month period, allowing for a minimum of 6 months follow up. Patients will undergo a CEUS examination within two weeks of their first two clinically indicated CT\u002FMRI exams (obtained at Jefferson 1-2 months and 4-6 months post TARE). In patients retreated prior to their 4-6 month MRI, CEUS may also be performed in the absence of the MRI at this time point but prior to retreatment. Patients will be recruited across six major hospitals within the Jefferson Health Enterprise. Those eligible for participation will be identified by project co-investigators and contacted by the study coordinator to discuss participation and to explain the study. The patient will be given time to consider the risks and benefits of the study and ask questions about participation. If agreeable, the patient will then arrange with the project coordinator to come to Jefferson's center city campus to sign consent and take part in the research study.",[27,28,88,89,90,91],"Liver Cancer","Hepatic Neoplasm","Primary Liver Cancer","Liver Neoplasm",[93,81,94,95,96,97,27,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115],"transarterial radioembolization","CEUS","contrast-enhanced ultrasound","hepatocellular","carcinoma","hepatocellular carcinoma (HCC)","liver cancer","liver tumors","liver lesions","microbubbles","liver parenchyma","liver imaging","HCC locoregional therapy","Ultrasound","Kupffer","Yttrium-90","tumor viability","time intensity curves","parametric maps","microbubble destruction","bolus contrast injection","CEUS biomarker","Y90 TARE","2026-06-08",{"date":118,"type":37},"2026-06-10",{"date":120,"type":37},"2025-09-11",{"date":122,"type":21},"2027-06-30",{"name":124,"class":44},"Thomas Jefferson University",{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100483897","phase-1-a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-enzelkitug-as-a-single-agent-and-in-combination-with-checkpoint-inhibitor-in-participants-with-locally-advanced-or-metastatic-solid-tumors-100483897","NCT05581004","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase Ia\u002FIb, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Life expectancy of at least 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Tumor specimen availability\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding or intention of becoming pregnant during the study or within 4 months after the final dose of enzelkitug, or 4 months after the final dose of pembrolizumab, or 5 months after the final dose of atezolizumab\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and\u002For radiotherapy, within 3 weeks prior to initiation of study treatment\n* Active hepatitis B (HBV) or hepatitis C (HCV) or tuberculosis\n* Positive test for human immunodeficiency virus (HIV) infection\n* Acute or chronic active Epstein-Barr virus (EBV) infection at screening\n* Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first enzelkitug infusion\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease\n* Prior allogeneic stem cell or organ transplantation",{"count":133,"type":21},450,[135],"PHASE1","This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.",[138,139,140,141,142,143,144,145,146,147,148,27],"Locally Advanced or Metastatic Solid Tumors","NSCLC","HNSCC","Melanoma","TNBC","Esophageal Cancer","Gastric Cancer","Cervical Cancer","Colorectal Cancer","Urothelial Carcinoma","Clear Cell RCC","2026-06-05",{"date":151,"type":37},"2026-06-09",{"date":153,"type":37},"2022-10-20",{"date":155,"type":21},"2028-07-31",{"name":157,"class":158},"Genentech, Inc.","INDUSTRY",41,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":45},"100572056","effect-of-the-hcc-liver-link-intervention-100572056","NCT06728293","Effect of the HCC Liver-Link Intervention","Inclusion Criteria\n\n• Within UCSF criteria:\n\nCandidates are eligible or a standardized MELD or PELD exception if, before completing locoregional therapy, they have lesions that meet one of the following criteria:\n\n* One Class 5 lesion greater than 5 cm and less than or equal to 8 cm\n* two or three Class 5 lesions that meeting all of the following\n\n  * At least one lesion greater than 3cm\n  * Each lesion less than or equal to 5 cm, and\n  * A total diameter of all lesions less than or equal to 8cm\n* Four or five Class 5 lesions each less than 3 cm, and a total diameter of all lesions less than or equal to 8 cm.\n* Between 18-75 years old\n* Have no more than two visits with an HCC-related provider\n* Able to read, write, and speak English\n* Any 1 of the following:\n\n  * Self-report as Black race (can be multiple races as long as 1 is Black)\n  * Self-report as insured by Medicaid (+\u002F- Medicare)\n  * SVI (Social vulnerability index) \\>= .75\n  * Unmarried\n\nExclusion Criteria\n\n* Lacks capacity to provide informed consent, including those with stage 2 HE or higher at the time of consent.\n* Age over 75\n* Last transthoracic echocardiogram with EF\\\u003C40% (OK if no prior echo)\n* BMI over 50\n* Patients who, in the investigator's judgment, are unlikely to ever be eligible for liver transplantation or resection at the time of enrollment, with reason documented\n* Prior history of any solid organ transplant\n* Non-skin cancer malignancies other than hepatocellular carcinoma in past 2 years unless approved by PI (i.e. cervical cancer, early prostate cancer)\n* Patients who have undergone resection or waitlisted\n* Patients near completion of transplant evaluation, PI to determine utility of intervention.","75 Years",{"count":168,"type":21},40,[24],"This study is a pilot, multi-center randomized controlled trial testing the HCC Liver-Link intervention, a culturally tailored, multi-level program designed to reduce racial disparities in hepatocellular carcinoma (HCC) care. The intervention combines: (1) patient education to improve HCC-related disease and treatment knowledge, (2) social needs and substance use screening with referral to social work and community resources, and (3) facilitated access to subspecialty cancer care through a multidisciplinary HCC tumor board.\n\nA total of 40 Black patients with Barcelona Clinic Liver Cancer (BCLC) stage 0, A, or downstaged B disease will be randomized to receive either the HCC Liver-Link intervention or usual care and followed for 6 months or until liver transplant waitlisting. Primary outcomes are time to receipt of curative therapies (liver transplantation or resection) and change in HCC-related knowledge. Findings will inform development of larger interventions to eliminate racial disparities in HCC outcomes.",[27,172],"Racial Disparities","2026-06-03",{"date":149,"type":37},{"date":176,"type":37},"2025-06-10",{"date":178,"type":21},"2027-01",{"name":180,"class":44},"Indiana University",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":206,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100509886","phase-1-fog-001-in-locally-advanced-or-metastatic-solid-tumors-100509886","NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors","A Phase 1\u002F2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function.\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic non-MSI-H or non-dMMR CRC.\n* At least one lesion that is suitable for a core needle biopsy.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):\n\n* Histologically, cytologically, or radiographically confirmed HCC with a documented WPAM (by local ctDNA or tumor NGS testing) in APC or CTNNB1\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d, Part 1h, and Part 2d):\n\n* Desmoid tumor (aggressive fibromatosis)\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n* One dose of mFOLFOX6 with or without bevacizumab in the unresectable or metastatic setting prior to enrollment is allowed.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab\n\n* Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.\n* MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1\u002FPD-L1\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine\u002FTipiracil + Bevacizumab\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2a):\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2b):\n\n* Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence\n\nExclusion Criteria:\n\n* Known history of bone metastasis. Bone metastasis are allowed for patients with mCRPC.\n* Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.\n* Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan.\n* Uncontrolled inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease)\n* Unstable\u002Finadequate cardiac function.\n* Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.\n* Pregnant, lactating, or planning to become pregnant.",{"count":189,"type":21},595,[135,56],"The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.",[193,146,194,195,196,197,27,198,199,200,201,202,203,204,205],"Cancer","Solid Tumor","Locally Advanced Solid Tumor","Metastatic Cancer","WNT Pathway","Desmoid","Microsatellite Stable Colorectal Cancer","Metastatic Castration-resistant Prostate Cancer","FAP","Endometrial Carcinoma","Prostate Cancer","Microsatellite Instability-High Colorectal Cancer","Adamantinomatous Craniopharyngioma",[193,194,195,196,207,208,209,198,210,211,212,213,214],"WNT Pathway Activating Mutation (WPAM)","Colorectal Cancer (CRC)","Microsatellite Stable (MSS)","Hepatocellular Carcinoma (HCC)","Adenomatous Polyposis Coli (APC)","β-catenin","Beta-catenin","CTNNB1","2026-05-26",{"date":217,"type":37},"2026-05-28",{"date":219,"type":37},"2023-05-23",{"date":221,"type":21},"2027-08-31",{"name":223,"class":158},"Parabilis Medicines, Inc.",33,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":74},"100549473","sbrt-in-hcc-with-oligoprogression-on-first-line-immunotherapy-100549473","NCT06434480","SBRT in HCC With Oligoprogression on First-line Immunotherapy","Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma With Oligoprogression on First-line Immunotherapy","Inclusion Criteria:\n\n1. Patients aged ≥ 18 years old\n2. ECOG performance 0 to 1\n3. Confirmed diagnosis of HCC\n4. Oligoprogression on first-line immunotherapy, as defined as ≤ 5 lesions (intra- and extrahepatic lesions all together; vascular tumor thrombus is counted as one lesion)\n\n   * First-line immunotherapy that are allowed in this study include atezolizumab plus bevacizumab, durvalumab plus tremelimumab, durvalumab, nivolumab and ipilimumab, which are approved by the FDA and have been used in Hong Kong.\n5. Progressed lesion(s) amenable to SBRT:\n\n   * For intrahepatic progression:\n\n     * Number of intrahepatic progression ≤ 5\n     * Total intrahepatic tumours ≤ 10\n     * Maximum sum of HCC ≤ 20cm\n     * Any one HCC ≤ 20cm\n     * Normal liver volume minus intrahepatic GTV \\> 700cc\n     * Mean liver dose ≤ 15Gy\n     * No measurable common or main branch biliary duct involvement\n     * No direct tumor invasion into the stomach, duodenum, small bowel or large bowel\n   * For extrahepatic progression:\n\n     * Maximal tumor size ≤ 7cm\n     * Respective dose constraints of organ at risks as listed on the UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy can be met and ASTRO guideline.\n6. Prior radiofrequency ablation (RFA) or trans-arterial chemoembolization (TACE) are eligible\n7. Child-Pugh A liver function\n8. Life expectancy longer than 12 weeks\n9. At least one measurable treatment lesion according to RECIST 1.1\n10. Written informed consent must be obtained prior to any study related procedures\n11. Adequate haematological function (Hb ≥ 8.5g\u002FdL; Plt ≥ 50x10\\^9\u002FL; ANC ≥ 1.0x10\\^9\u002FL; INR ≤ 1.5)\n12. Adequate hepatic function (albumin ≥ 28g\u002FL; Bilirubin ≤ 2.5xULN; ALT \\\u003C 5 times upper limit normal)\n13. Adequate renal function (serum creatinine ≤ 1.5 times the upper limit of normal range; Na ≥ 130mmol\u002FL; K ≥ 3.0mmol\u002FL)\n14. Able to read, understand and provide written consent\n\nExclusion Criteria:\n\n1. History of another malignancy except appropriately-treated BCC of skin or CIN of cervix during the last 5 years\n2. Previous radiotherapy to the abdomen\n3. Previous yttrium-90 chemoembolization\n4. Repetitive history of non-healing wounds or ulcers within 2 months of inclusion\n5. Pregnant or lactating females at any time during the study\n6. Active autoimmune disease requiring systemic therapy in the past 2 years\n7. Diagnosis of immunodeficiency (including HIV)\n8. Ongoing corticosteroid therapy \\>10mg prednisone daily",{"count":84,"type":21},[24],"HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong. Patients with advanced HCC are treated with immunotherapy-based as first-line treatment as a standard of care. At the moment, there is limited evidence to guide subsequent treatments after patients progressed on immunotherapy. Oligoprogression is a term used to describe patients who had limited progression (usually less than 3 sites) on systemic therapy, with the rest of the lesions controlled. Previous studies in non-HCCs have shown that addition of locoregional treatment (e.g. radiotherapy) may prolong the use of systemic therapy, resulting in improved survival, but this has been relatively unexplored for HCC. In this prospective, single-arm study, we aim to evaluate the treatment outcome, efficacy and safety of the addition of radiotherapy to oligoprogressive sites for patients who had limited progression on First-line Immunotherapy.",[27],[237],"SBRT in HCC","2026-05-14",{"date":240,"type":37},"2026-05-18",{"date":242,"type":37},"2024-06-21",{"date":244,"type":21},"2028-03-01",{"name":246,"class":44},"Chinese University of Hong Kong",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":74},"100638843","phase-2-a-study-of-vrt106-combined-with-camrelizumab-and-apatinib-for-advanced-hcc-100638843","NCT07589244","A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC","A Multicenter, Open-label Phase II\u002FIII Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form (ICF), understand the nature of this study, and agree to comply with and complete all required study procedures.\n* Be aged between 18 and 75 years (inclusive) on the date of signing the ICF, regardless of gender.\n* Have a histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC), or a clinical diagnosis of advanced HCC according to the Standard for Diagnosis and Treatment of Primary Liver Cancer(2024 Edition).\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Have an anticipated life expectancy of ≥ 3 months.\n* Have no severe hematologic, hepatic, renal, coagulation, or cardiac function abnormalities.\n\nExclusion Criteria:\n\n* Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therapies.\n* Receipt of other unapproved investigational drugs\u002Fdevices within 4 weeks or 5 half-lives (whichever is shorter) prior to first dose administration in this study, or immunocompromised status.\n* History of splenectomy.\n* Pregnant or breastfeeding women.",{"count":255,"type":21},66,[56,257],"PHASE3","This is an open-label phase II\u002FIII clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).",[27],[27],"2026-05-13",{"date":263,"type":37},"2026-05-15",{"date":261,"type":21},{"date":266,"type":21},"2029-06-30",{"name":268,"class":158},"Guangzhou Virotech Pharmaceutical Co., Ltd.",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":279,"conditions":280,"keywords":284,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":45},"100392492","optimizing-y90-therapy-for-radiation-lobectomy-100392492","NCT04390724","Optimizing Y90 Therapy for Radiation Lobectomy","Yttrium-90 Radiation Lobectomy: Dose Optimization and Prediction of FLR Hypertrophy to Enable Resection of HCC","Inclusion Criteria:\n\n1. Patients must have been diagnosed with HCC confirmed by histology or must meet one of the following American Association for the Study of Liver Diseases (AASLD) guidelines:\n\n   * AFP \\>200 and radiological evidence (arterial hypervascularity) of lesion \\> 2 cm does not require biopsy\n   * Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy\n   * One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy\n2. Child-Pugh stage A\n3. Future Liver Remnant (FLR) of \\\u003C 40%\n4. ECOG Performance Status 0-1\n5. Bilirubin ≤ 3.0 mg\u002Fdl- Treatment may proceed if the Bilirubin is elevated if the tumor may be isolated from a vascular standpoint\n6. Creatinine ≤ 2.0 mg\u002Fdl\n7. ANC ≥ 1.5 K\u002FuL\n8. Platelets \\> 25 K\u002FuL\n9. Patient is willing participate in this study and has signed the consent\n10. For Group 2 patients only:\n\n    * Patients planned Y90 dose and embolic load is found to fall within the optimal dose and embolic load size from data from Group 1 patients\n\nExclusion Criteria:\n\n1. Patient must not be pregnant\n\n   NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n   * Has not undergone a hysterectomy or bilateral oophorectomy\n   * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n2. For Patients in Group 2 only:\n\n   * Patients who have contraindications to MRI:\n\n     * Patients that are claustrophobic and haven't been able to tolerate an MRI in the past. (Patients with mild claustrophobia are eligible and have the option to take\n\n       1mg oral Lorazepam prior to the MRI, if needed)\n     * Allergy to gadolinium-containing contrast media\n     * Patients with a pacemaker, metallic clip, aneurysm clips, shrapnel fragments, etc.\n     * Patients with an eGFR \\\u003C 30 mL\u002Fmin\u002Fm²\n3. Must not have any significant life-threatening extra-hepatic disease or life- threatening secondary malignancies, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be HIV positive or have acute HBV or HCV\n4. Must not have any contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents (e.g. closure device)\n5. Must not have any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere treatment, in the Investigator's judgment\n6. History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically\n\n   \\-",{"count":277,"type":21},104,"OBSERVATIONAL","HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.",[27,281,282,196,283],"Resection","Transplant","Adult Primary Liver Cancer",[27,285,286,287,88],"Y90 Radioembolization","Liver Resection","Liver Transplant","2026-03-23",{"date":290,"type":37},"2026-03-27",{"date":292,"type":37},"2020-07-17",{"date":294,"type":21},"2026-07",{"name":296,"class":44},"Northwestern University",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":45},"100579367","phase-2-sbrt-with-immunotherapy-and-atezo-bev-in-hcc-with-major-portal-vein-thrombosis-100579367","NCT06823375","SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis","Stereotactic Body Radiotherapy With Immunotherapy (Atezolizumab Plus Bevacizumab) in Patients With Advanced HCC and Major Portal Vein Tumour Thrombosis","Inclusion Criteria:\n\n* Patients aged ≥ 18 years old\n* ECOG performance 0 to 1\n* Confirmed diagnosis of HCC (either histologic or cytologic analysis, or clinical features according to the American Association for the Study of Liver Diseases)\n* Presence of major portal vein thrombosis (Vp3 \\[first-order tumour thrombosis in portal vein\\] or Vp4 \\[tumour thrombosis in the main portal vein, or portal vein branch in contralateral lobe\\]), limited to the liver and should be amenable to SBRT\n* No disease progression after 2 cycles of atezolizumab plus bevacizumab\n* Presence of ≤5 lesions within the liver\n* Gastric or esophageal varices must be screened; if interventions were performed, repeated upper endoscopy is needed to confirm healing of treated varices\n* Child-Pugh A liver function\n* Life expectancy longer than 3 months\n* At least one measurable treatment lesion according to RECIST 1.1\n* Extrahepatic metastases are allowed, limited to 3 sites, and not causing functional compromise\n* Written informed consent must be obtained prior to any study related procedures\n* Adequate haematological function (Hb ≥ 8.5g\u002FdL; Plt ≥ 75x109\u002FL; ANC ≥ 1.5x109\u002FL; INR ≤ 1.5)\n* Adequate hepatic function (albumin ≥ 28g\u002FL; Bilirubin ≤ 40 μmol\u002FL; ALT \\\u003C 5 times upper limit normal)\n* Adequate renal function (serum creatinine ≤ 2 times the upper limit of normal range; Na ≥ 130mmol\u002FL; K ≥ 3.0mmol\u002FL)\n* Able to read, understand and provide written consent\n\nExclusion Criteria:\n\n* History of another malignancy except appropriately-treated BCC of skin or CIN of cervix during the last 5 years\n* History of rupture HCC in the past 3 months\n* History of gastric or esophageal varices with interventions performed within 1 month\n* Tumour thrombosis that extends beyond the portal vein (e.g. inferior vena cava, superior vena cava)\n* Liver tumours occupy ≥ 50% of liver\n* Previous radiotherapy to the abdomen\n* Previous yttrium-90 chemoembolization\n* Repetitive history of non-healing wounds or ulcers within 2 months of inclusion\n* Pregnant or lactating females at any time during the study\n* Active autoimmune disease requiring systemic therapy in the past 2 years\n* Diagnosis of immunodeficiency (including HIV)\n* Ongoing corticosteroid therapy \\>10mg prednisone daily",{"count":168,"type":21},[56],"Patients with PVTT involvement is a significant healthcare burden as they are present in up to 40% of patients with HCC at diagnosis. These patients exhibit a poorer prognosis compared to patients without PVTT, as a result they were often excluded from existing pivotal clinical trials \\[9-11\\]. Without management, the median OS in affected patients could be as short as 2 to 4 months. The role of liver-directed therapies is limited for patients with major PVTT. For example, percutaneous ablation to PVTT is technically challenging, especially for centrally located PVTT due to their proximity to hepatic vasculature and bile ducts. Transarterial therapies are contraindicated for patients with major PVTT due to risk of concurrent interruption of both hepatic arterial and portal venous blood flow resulting in severe liver ischemia. Therefore, patients with major PVTT are recommended to receive systemic treatment by international guidelines. Yet, the OS for patients with main PVTT remained poor. In the exploratory analysis of IMbrave-150, patients with main PVTT who received atezolizumab plus bevacizumab had a median OS of 7.6 months only, compared to 21.1 months for those without PVTT. There is a huge unmet for this group of patients with dismal prognosis.\n\nSBRT is a radiotherapy technique that enables delivery of high dose of radiation in an extremely precise manner. Compared to more conventional radiotherapy techniques such as intensity modulated radiotherapy (IMRT), SBRT has the advantage of superior disease control, minimizing dose to normal tissue and toxicity, and reduction of overall treatment time. For patients with PVTT, a number of retrospective and prospective trials have shown that SBRT can offer durable local control for patients with PVTT involvement. For instance, a randomized trial conducted in Korean which compared the combination of TACE-radiation (TACE-RT) with sorafenib, involving 90 patients with Child-Pugh A HCC with macrovascular invasion (MVI) (35% had main or bilateral portal vein involvement), showed improved 12-week PFS (86.7% vs. 34.3%), time-to-progression (31.0 vs. 11.7 weeks; p\\\u003C0.001), and OS (55.0 vs. 43.0 weeks; p=0.04) with TACE-RT. In a Canadian single-center retrospective study including 128 patients with HCC and MVI treated with SBRT between 2003 to 2016, 1-year local control was 87.4% and median OS was 18.3 months.\n\nGiven the existing evidence, it would be of interest to study the efficacy and safety of atezolizumab plus bevacizumab and SBRT to portal venous tumour thrombosis in this patient group.",[27],[237,309],"major portal vein thrombosis","2026-03-02",{"date":312,"type":37},"2026-03-04",{"date":314,"type":37},"2025-07-10",{"date":155,"type":21},{"name":246,"class":44},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":74},"100610109","phase-2-regulus-mri-guided-adaptive-sabr-for-liver-cancers-100610109","NCT07223307","REGULUS: MRI-guided Adaptive SABR for Liver Cancers","Phase II Trial of REal Time MRI GUided Adaptive Stereotactic Ablative Radiotherapy for Liver Cancers Using a Single Session, Simulation Free Workflow","Inclusion Criteria:\n\n* Histologically confirmed HCC, intrahepatic cholangiocarcinoma, or metastatic cancer. In the case of suspected HCC in patients with known cirrhosis, noninvasive criteria recommended by the European Association for the Study of Liver Diseases (lesion \\> 1 cm with arterial phase hyperenhancement and venous phase washout) or LI-RADS score of 5 may be used\n* ≥ 18 years old at time of study enrollment\n* Child-Pugh A status\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Life Expectancy \\> 6 months\n* For women of childbearing potential or who are not postmenopausal (see Appendix F for Definition of Menopausal Status), a negative urine or serum pregnancy test must be done.\n* Ability to understand and the willingness to provide written informed consent.\n* Patients treated with prior liver-directed therapies with the exception of radioembolization are eligible for this study if they otherwise meet eligibility criteria\n\nExclusion Criteria:\n\n* Prior treatment with radioembolization\n* Cytotoxic chemotherapy or investigational agent within 1 week of SABR\n* Prior radiotherapy overlapping with study treatment site\n* Female patients who are pregnant\n* Contraindication to having an MRI scan or inability to tolerate MRI\n* Presence of a pacemaker or other implanted cardiac device\n* Direct tumor extension into the stomach, duodenum, small bowel or large bowel\n* Patient unable to breath hold \\> 15 seconds",{"count":325,"type":21},62,[56],"Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers",[88,329,330,27],"Intrahepatic Cholangiocarcinoma","Liver Metastases","2026-02-05",{"date":333,"type":37},"2026-02-09",{"date":335,"type":37},"2026-01-23",{"date":337,"type":21},"2030-01",{"name":339,"class":44},"Stanford University",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":347,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100622120","adjuvant-anti-pd-1-therapy-in-resected-hepatocellular-carcinoma-100622120","NCT07379489","Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma","Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 75;\n* achieved complete tumor resection;\n* histological verification of HCC;\n* liver function classified as Child-Pugh grade A or B;\n* No other serious systemic disease or organ dysfunction.\n\nExclusion Criteria:\n\n* history of other malignancies or recurrent HCC;\n* extrahepatic metastasis;\n* prior treatments for HCC;\n* ongoing severe postoperative complications;\n* mixed or other types of liver cancer;\n* received other adjuvant therapy.",{"count":348,"type":21},300,"Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.",[27,351,352,353],"Adjuvant Therapy","Recurrence","Immune Checkpoint Inhibitor","NOT_YET_RECRUITING",{"date":356,"type":37},"2026-01-30",{"date":358,"type":21},"2026-01-31",{"date":360,"type":21},"2031-12-31",{"name":362,"class":44},"Tongji Hospital",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":380,"leadSponsor":382,"locationsCount":74},"100620108","preliminary-evaluation-of-clinical-application-of-spect-imaging-targeting-gpc3-100620108","NCT07353333","Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3","Inclusion Criteria:\n\n1. the subject or his\u002Fher legal representative can sign and date the informed consent form\n2. commitment to follow the research procedures and cooperate in the implementation of the full-process research\n3. patients with high clinical suspicion or histopathology diagnosis of HCC and generally in good condition\n4. patients with a history of hepatocellular carcinoma who recur after treatment\n5. women in their reproductive years were using contraception for at least one month before screening and were committed to using contraception throughout the study period and for the prescribed period after the end of the study\n\nExclusion Criteria:\n\n1. inability to complete SPECTCT examination (including inability to lie down, claustrophobia, radiophobia, etc.)\n2. acute systemic diseases and electrolyte disorders\n3. patients with known hypersensitivity to GPC3 imaging agents or synthetic excipients\n4. patients considered by the investigator to have poor adherence\n5. pregnant or lactating patients\n6. Have other factors not suitable to participate in this test","80 Years",{"count":371,"type":21},6,[24],"This project will target patients with highly clinically suspected or histopathology diagnosed hepatocellular carcinoma (HCC) using targeted GPC3-specific imaging agents (e.g. , Iodine-131-aGPC3-Scfv) for integrated SPECTCT imaging, to evaluate the pharmacokinetics distribution of the targeted drug in patients with hepatocellular carcinoma (HCC) by low-dose integrated diagnosis and treatment (i.e. , Iodine-131-RRB- imaging, to determine the metabolism, safety and tolerability of the drug in vivo Secondary objective: to evaluate the targeting of GPC3-SPECIFIC imaging agents in patients with hepatocellular carcinoma to assess the feasibility of this targeted agent for future treatment.",[27,375],"SPECT-CT","2026-01-19",{"date":378,"type":37},"2026-01-20",{"date":356,"type":21},{"date":381,"type":21},"2026-12-30",{"name":383,"class":44},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":74},"100620006","phase-2-sintilimab-combined-with-stereotactic-body-radiotherapy-as-neoadjuvant-therapy-for-resectable-hepatocellular-100620006","NCT07352007","Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular","A Prospective, Randomized Controlled, Phase II Study of Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Written informed consent must be provided and signed prior to the implementation of any trial-related procedures.\n2. Male or female subjects aged ≥18 years and ≤75 years.\n3. ECOG PS score of 0-1.\n4. BCLC 0-B.\n5. Diagnosed with HCC according to the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition).\n6. CNLC Stage IA-IIB.\n7. Child-Pugh score of ≤7.\n8. No prior systemic antitumor therapy for hepatocellular carcinoma.\n9. Assessed as suitable for R0 resection surgery.\n10. Assessed as having no contraindications to SBRT and immunotherapy.\n11. Estimated life expectancy of \\>3 months.\n12. At least one measurable lesion according to RECIST 1.1 or mRECIST criteria.\n13. Adequate organ and bone marrow function, defined as follows:a) Hematology: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; Platelet count (PLT) ≥75×10⁹\u002FL; Hemoglobin (HGB) ≥9.0 g\u002FdL.b) Liver function: Serum total bilirubin (TBIL) ≤3 × upper limit of normal (ULN); Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤5 × ULN; Serum albumin ≥28 g\u002FL.c) Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); Urinalysis shows urine protein \\\u003C2+; For patients with baseline urinalysis showing urine protein ≥2+, a 24-hour urine collection must demonstrate 24-hour urine protein \\\u003C1 g.d) Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n14. For subjects with acute or chronic active hepatitis B or C infection, continuous antiviral therapy must be administered during the study period.\n15. For female subjects of childbearing potential, a negative urine or serum pregnancy test must be confirmed within 3 days prior to receiving the first dose of the study drug (Cycle 1, Day 1). If a urine pregnancy test is inconclusive, a blood pregnancy test is required. Non-childbearing potential is defined as being post-menopausal for at least 1 year, or having undergone surgical sterilization or hysterectomy.\n16. If there is a risk of conception, all subjects (both male and female) must use highly effective contraceptive methods (with a failure rate of \\\u003C1% per year) throughout the entire treatment period and for at least 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy). Estimated life expectancy ≥12 weeks.\n\nExclusion Criteria:\n\n1. History of any histologically\u002Fcytologically confirmed malignancy other than HCC.\n2. History of hepatic encephalopathy, or history of liver transplantation.\n3. Presence of any extrahepatic metastatic lesions.\n4. Prior receipt of any systemic antitumor therapy for HCC, including treatment with antibodies such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents.\n5. Acute or chronic active hepatitis B or C infection, defined as: Hepatitis B virus (HBV) DNA \\>2000 IU\u002FmL or 10⁴ copies\u002FmL; Hepatitis C virus (HCV) RNA \\>10³ copies\u002FmL; Co-positive for Hepatitis B surface antigen (HBsAg) and anti-HCV antibody.\n6. Radiotherapy received within 3 weeks prior to the first dose.\n7. Human Immunodeficiency Virus (HIV) infection (positive HIV 1\u002F2 antibodies) or known active syphilis infection.\n8. Severe infections that are either active or poorly controlled clinically.\n9. Active autoimmune disease that required systemic treatment within the past 2 years prior to the first dose.\n10. Known history of primary immunodeficiency. The presence of autoimmune antibodies alone requires the investigator's judgment to confirm the presence of an autoimmune disease.\n11. Use of immunosuppressive medication within 4 weeks prior to the first dose, with the exception of intranasal, inhaled, or other routes of locally administered corticosteroids, or systemic corticosteroids at physiological doses (i.e., not exceeding 10 mg\u002Fday prednisone or an equivalent dose of other corticosteroids). Temporary use of corticosteroids for conditions such as asthma or COPD for dyspnea is permitted.\n12. Administration of any live attenuated vaccine within 4 weeks prior to the first dose or planned administration during the study period.\n13. Any local therapy for liver cancer received within 4 weeks prior to the first dose.\n14. Diagnosis of another malignancy within 5 years prior to the first dose, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For carcinoma in situ that has undergone radical resection. If another malignancy or HCC was diagnosed more than 5 years prior to the first dose, pathological or cytological confirmation is required for any recurrent or metastatic lesions.\n15. Known allergy to any component of the Sintilimab formulation; or history of severe allergic reactions to other monoclonal antibodies or tyrosine kinase inhibitors.\n16. Treatment received as part of another clinical trial within 4 weeks prior to the first dose.\n17. Female patients who are pregnant or breastfeeding.\n18. Any other acute or chronic disease, psychiatric disorder, or abnormal laboratory test value that may lead to the following outcomes: increased risk associated with study participation or study drug administration, interference with the interpretation of study results, and based on the investigator's judgment, makes the patient unsuitable for participation in this study.",{"count":392,"type":21},110,[56],"This study is a prospective, randomized controlled, phase II trial evaluating the efficacy and safety of neoadjuvant therapy with Sintilimab combined with SBRT in patients with resectable hepatocellular carcinoma.\n\nAfter meeting the inclusion and exclusion criteria and providing informed consent, eligible subjects will be randomly assigned to the experimental group or the control group:\n\n* Experimental Group: Subjects will receive Sintilimab 200 mg via intravenous infusion on day 1 of each 3-week cycle, for a total of two cycles. This will be combined with SBRT, administered as 8 Gy per fraction for 3 fractions on days 1, 3, and 5. Surgery will be performed 4-6 weeks after the last treatment, following the assessment of the patient's condition. Postoperative adjuvant therapy with Sintilimab monotherapy (200 mg Q3W) will be administered until disease recurrence, death, intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, or other protocol-specified reasons occur, for a maximum of one year.\n* Control Group:Subjects will undergo surgery directly. Postoperative adjuvant therapy with Sintilimab monotherapy (200 mg Q3W) will be administered until disease recurrence, death, intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, or other protocol-specified reasons occur, for a maximum of one year.",[27],"2026-01-11",{"date":378,"type":37},{"date":399,"type":21},"2025-12-28",{"date":401,"type":21},"2031-01-20",{"name":403,"class":44},"Lei ZHAO",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":74},"100619915","predictive-value-of-minimal-residual-disease-for-postoperative-recurrence-and-adjuvant-pd-1-inhibitor-in-hcc-100619915","NCT07350824","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in Hepatocellular Carcinoma: A Prospective, Multicenter Study","Inclusion Criteria:\n\n* Age between 18 and 75 years, inclusive, regardless of gender.\n* Newly diagnosed, treatment-naïve patients with HCC.\n* Received radical treatments, such as liver resection or microwave ablation.\n* Combine at least one of the risk factors for tumor recurrence, such as microvascular\u002Fmacrovascular invasion, poor differentiation, satellite nodules, multiple tumors, and tumor diameter greater than 5 cm.\n* Child-Pugh liver function score ≤ 7.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Absence of severe organic diseases affecting the heart, lungs, brain, or other major organs.\n\nExclusion Criteria:\n\n* History of other malignancies.\n* Recurrent HCC.\n* Prior systemic therapy for HCC.\n* Unable to complete the follow-up and dynamic MRD monitoring.\n* Having an immune deficiency disorder.\n* Allergic to PD-1 inhibitors or unable to tolerate related treatments.",{"count":412,"type":21},276,[24],"Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge. Adjuvant immune checkpoint inhibitors (ICIs) show promise in improving outcomes, but biomarkers to identify patients who will benefit are lacking. Current clinicopathological risk factors for minimal residual disease (MRD) are suboptimal in sensitivity and specificity.\n\nCirculating tumor DNA (ctDNA) analysis, reflecting real-time tumor dynamics, offers a promising approach for MRD detection. This study focuses on the methylation status of GNB4 and Riplet-genes located within HCC-associated CpG islands-using a bespoke bisulfite-conversion and qPCR assay to sensitively detect methylated alleles, thereby enabling MRD monitoring.\n\nTo clinically validate this approach, we will conduct a prospective, multicenter cohort study assessing the predictive value of serial \\*GNB4\u002FRiplet\\* methylation testing for recurrence and adjuvant therapy benefit.",[27,416,352],"Minimal Residual Disease","2026-01-09",{"date":378,"type":37},{"date":420,"type":21},"2025-12-31",{"date":422,"type":21},"2028-12-31",{"name":362,"class":44},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":443},"100619857","phase-2-tace-combined-with-tislelizumab-lenvatinib-and-carvedilol-for-unresectable-hcc-with-cirrhotic-portal-hypertension-100619857","NCT07350070","TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension","TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for the Treatment of Unresectable Hepatocellular Carcinoma With Cirrhotic Portal Hypertension: A Multicenter, Simon Two-Stage, Single-Arm Study","Inclusion Criteria:\n\n* Aged 18-75 years.\n* At least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (tumor lesion long axis ≥10 mm on CT scan).\n* Newly diagnosed hepatocellular carcinoma without any prior treatment for HCC.\n* Child-Pugh liver function score ≤ 7.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.\n* Absence of severe organic diseases affecting major organs (e.g., heart, lung, brain).\n* Compensated cirrhosis with clinically significant portal hypertension (meeting any one of the following criteria):\n\n  1. Imaging evidence (ultrasound, CT, or MRI) of portosystemic collateral circulation.\n  2. Endoscopic evidence of esophageal or gastric varices.\n  3. Liver stiffness measurement (LSM) \\>25 kPa; or LSM 20-25 kPa with platelet count \\\u003C150×10⁹\u002FL; or LSM 15-20 kPa with platelet count \\\u003C110×10⁹\u002FL.\n\nExclusion Criteria:\n\n* Decompensated cirrhosis.\n* Concurrent other malignancies or recurrent HCC.\n* Any active, known, or suspected autoimmune disease.\n* History of allergy to any component of PD-1 inhibitors, lenvatinib, or carvedilol.\n* Severe concurrent medical conditions, including asthma, significant cardiac conduction block, and sinus bradycardia.\n* Known human immunodeficiency virus (HIV) infection; or active hepatitis (e.g., hepatitis B\u002FC virus infection).\n* Presence of tumor thrombus in the inferior vena cava, hepatic vein, or main portal vein.",{"count":432,"type":21},78,[56],"In China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically significant portal hypertension (CSPH). CSPH not only limits treatment options and worsens prognosis but also leads to the frequent exclusion of such patients from pivotal clinical trials, resulting in a lack of high-level evidence for their management. Carvedilol, a non-selective beta-blocker, is a first-line therapy for portal hypertension. Emerging evidence suggests that this drug class may also modulate the tumor microenvironment and enhance the efficacy of immune checkpoint inhibitors.\n\nTo address this unmet need, this study aims to explore a novel quadruple-therapy strategy (TACE + tislelizumab + lenvatinib + carvedilol) for the treatment of unresectable HCC with concurrent cirrhotic portal hypertension. The rationale is twofold: while controlling portal hypertension and safeguarding treatment safety, carvedilol may also potentiate immunotherapy by modulating adrenergic signaling, thereby achieving dual benefits of \"liver protection\" and \"anti-cancer\" synergy. Utilizing an efficient Simon's two-stage design, this study will conduct a preliminary assessment of the regimen's efficacy and safety with minimal risk, providing essential data to inform future confirmatory research.",[27,436,437],"Liver Cirrhosis","Portal Hypertension",{"date":378,"type":37},{"date":420,"type":21},{"date":441,"type":21},"2028-06-30",{"name":362,"class":44},7,{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":451,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":460,"locationsCount":4},"100619121","tace-versus-haic-combined-with-pd-1-inhibitors-and-lenvatinib-for-unresectable-hepatocellular-carcinoma-100619121","NCT07340502","TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma","TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma: a Multicenter, Prospective, Observational Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 75 years;\n* Tumor stage classified as BCLC-A to -C, with no evidence of extrahepatic metastasis;\n* Newly diagnosed, treatment-naïve hepatocellular carcinoma with no prior anticancer therapy;\n* Child-Pugh liver function score ≤ 7;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1;\n* Absence of severe organic diseases affecting major organs (e.g., heart, lung, brain).\n\nExclusion Criteria:\n\n* Decompensated liver cirrhosis;\n* Concurrent other malignancies or recurrent hepatocellular carcinoma;\n* Any active, known, or suspected autoimmune disease;\n* History of hypersensitivity to any component of PD-1 inhibitors or lenvatinib;\n* Human immunodeficiency virus (HIV) infection; or active viral hepatitis (e.g., hepatitis B or C);\n* Tumor thrombus involving the inferior vena cava, hepatic veins, or the main portal vein trunk.",{"count":452,"type":21},364,"Although the combination of transarterial chemoembolization (TACE) with PD-1 inhibitor plus lenvatinib has become a new standard, the therapeutic efficacy for unresectable hepatocellular carcinoma (uHCC) still requires improvement, as TACE remains limited for patients with multifocal lesions, hypovascular tumors, or those complicated with portal vein tumor thrombosis (PVTT). Hepatic arterial infusion chemotherapy (HAIC), as an alternative locoregional therapy, has demonstrated advantages in treating these refractory cases. Therefore, this study innovatively designs a prospective cohort study to conduct a comparison of the two triple-combination regimens-\"HAIC plus PD-1 inhibitor and lenvatinib\" versus \"TACE plus PD-1 inhibitor and lenvatinib\"-in terms of real-world efficacy and safety, with a focus on enrolling patients who are likely to have suboptimal responses to TACE. This research aims to provide high-level evidence for selecting the optimal combined locoregional strategy for uHCC patients, thereby directly guiding clinical practice and potentially advancing the optimization of treatment strategies and personalized precision medicine to improve patient survival outcomes.",[27],"2026-01-06",{"date":457,"type":37},"2026-01-14",{"date":358,"type":21},{"date":422,"type":21},{"name":362,"class":44},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":484},"100618658","phase-2-a-study-of-yttrium-90y-microsphere-injection-in-combination-with-targeted-immunotherapy-in-the-treatment-of-hcc-100618658","NCT07334483","A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC","A Randomized, Active-Controlled, Open-Label Study of Yttrium [90Y] Microsphere Injection in Combination With Camrelizumab and\u002For Apatinib and Yttrium [90Y] Microsphere Injection Alone Versus cTACE in the Treatment of HCC","Inclusion Criteria:\n\n1. Patients who voluntarily participate in this study, sign the informed consent form (ICF), and are able to comply with the diagnosis, treatment, observation, follow-up visit and related procedures specified in this protocol, with good compliance.\n2. Patients aged ≥ 18 and ≤ 75, regardless of gender.\n3. HCC confirmed by pathological histology\u002Fcytology, or meeting the clinical diagnostic criteria in the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) established by the National Health Commission.\n4. Patients who are not suitable for surgery (including hepatectomy and liver transplantation) or ablation treatment based on the judgment of investigator or clinical practice guidelines, or refuse surgery or ablation treatment.\n5. China Liver Cancer Clinical Staging (CNLC): Ib-IIIa. Vp4 portal vein tumor thrombus invasion will be excluded, if combined with Vp1-3 portal vein tumor thrombus, the tumor thrombus must be located on the same side of the liver lobe as the targeted tumor area.\n6. Patients with at least 1 measurable lesion according to RECIST v1.1 and mRECIST criteria.\n7. Patients who have been evaluated by Yttrium \\[90Y\\] Microsphere Injection Selective Internal Radiation Therapy and Dose Evaluation Committee as suitable for SIRT treatment.\n8. For yttrium \\[90Y\\] microsphere injection, camrelizumab and apatinib, there are no contraindications for use in the product instructions and clinical practice guidelines. Patients who are suitable for cTACE treatment, have no contraindications to use in clinical practice guidelines, are expected to be able to use up to 4 cTACE treatments for localized liver lesions within 24 weeks during the study period, and are expected to receive 1-2 cTACE treatments for a single lesion.\n9. ECOG PS score: 0-1.\n10. Child-Pugh liver function classification: Class A or Class B with ≤7 points.\n11. Life expectancy ≥3 months.\n12. If the subject has HBV or HCV infection, the following criteria must be met:\n\n    i. Subjects with HBV infection (HBsAg and\u002For HBV-DNA positive): Subjects should receive antiviral treatment with one of the 4 drugs recommended by the national clinical guidelines for hepatitis B (tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, tenofovir amibufenamide and entecavir) for at least 7 days before the first study treatment to achieve HBV-DNA \\\u003C 2000 IU\u002FmL or \\\u003C 104 copies\u002FmL. The standardized antiviral treatment must be received throughout the study.\n\n    ii. If HCV-Ab is positive, the blood HCV RNA must be negative.\n13. Patients who have basically normal organ and bone marrow functions:\n\n    i. Hematology (corrective treatment such as any blood components or cell growth factors is not allowed within 7 days before the laboratory tests): Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; platelet count (PLT) ≥ 75 × 109\u002FL; hemoglobin (HGB) ≥ 90 g\u002FL.\n\n    ii. Liver function (human albumin or plasma transfusion is not allowed within 7 days before the laboratory tests): Serum total bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN, alkaline phosphatase (ALP) ≤ 5 × ULN; serum albumin ≥ 30 g\u002FL.\n\n    iii. Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN, or the calculated value of creatinine clearance (CrCI, estimated according to Cockcroft-Gault formula) ≥ 50 mL\u002Fmin. Urinalysis results show that urine protein is \\\u003C 2+ (if urine protein is ≥ 2+, the 24-hour urine protein quantitative test should be performed, and patients can be enrolled if the 24-hour urine protein quantification is \\\u003C 1.0 g).\n\n    iv. Coagulation function: International normalized ratio (INR) ≤ 1.8, or prothrombin time (PT) exceeds the range of normal control ≤ 4 seconds.\n14. Patients of childbearing potential should use effective contraceptive measures from the signing of the ICF to at least 3 months after the last study treatment.\n\nExclusion Criteria:\n\n1. Cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma confirmed by pathological histology or cytology.\n2. Invasive HCC, that is, imaging shows that microscopic or small tumor nodules are diffusely distributed in a certain liver lobe or the entire liver.\n3. Based on liver volume, the tumor burden is relatively large (\\>50%).\n4. Presence of hepatic vein or inferior vena cava tumor thrombus, or involvement of the superior mesenteric vein or more distant end.\n5. Patients with other malignant tumors other than HCC within 5 years or at the same time. However, patients with cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ and breast cancer in situ can be enrolled.\n6. Conversion therapies such as interventional and targeted immunotherapy have been used before hepatectomy, including conversion of functional residual liver volume (using ALPPS or PVE) and oncology conversion therapy.\n7. Previous systemic anti-tumor treatment for HCC, including molecular targeted drugs, systemic chemotherapy and immunotherapy (immune checkpoint inhibitors, antibody-drug conjugate \\[ADC\\], immune cells, oncolytic viruses and tumor vaccines, etc.).\n8. Use of Chinese patent medicines and modern Chinese medicine preparations with anti-liver cancer indications within 7 days before randomization.\n9. Previous local treatment for liver lesions, including TACE, transarterial embolization (TAE), hepatic artery infusion chemotherapy (HAIC), radiotherapy, or ablation of target liver lesions, injection of oncolytic viruses, and internal\u002Fexternal radiation therapy. In the case of adjuvant therapy after radical resection, patients who have only received one TACE can be enrolled.\n10. Previous solid organ (such as liver transplantation) or allogeneic stem cell transplantation (except for patients who have only received corneal transplantation).\n11. Patients with bile duct obstruction due to any reason that has not been resolved before randomization.\n12. Patients with decompensated cirrhosis and severe liver function impairment (Child-Pugh Grade C) before randomization, including severe jaundice, hepatic encephalopathy, hepatorenal syndrome or refractory ascites (i.e. clinically symptomatic moderate or severe ascites requiring therapeutic puncture, drainage or Child-Pugh ascites score \\> 2).\n13. Patients with clinically symptomatic pleural effusion and pericardial effusion requiring puncture and drainage before randomization. However, patients who have received puncture and drainage within 2 weeks before enrollment and only show a small amount of effusion on imaging without clinical symptoms can be enrolled.\n14. History of iodine contrast agent allergy of grade II or above, or inability to undergo enhanced liver CT scan due to any reason.\n15. Patients who are unable to swallow the drug, have malabsorption syndrome, incomplete gastrointestinal obstruction or any condition that significantly affects the gastrointestinal absorption of apatinib mesylate before randomization.\n16. History of active pulmonary tuberculosis. For subjects suspected of having active pulmonary tuberculosis, the definitive diagnosis should be made in combination with chest imaging, sputum, clinical symptoms and signs.\n17. Patients with congenital or acquired immune deficiency (such as HIV infection), active syphilis, or co-infection of hepatitis B and C.\n18. Patients with clinically significant cardiovascular and cerebrovascular diseases before randomization:\n\n    i. Uncontrollable hypertension (systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg) after optimal antihypertensive treatment, with a previous history of hypertensive crisis or hypertensive encephalopathy.\n\n    ii. History of myocardial infarction, unstable angina pectoris, cerebral infarction, cerebral haemorrhage or any other major cardiovascular and cerebrovascular accident within 6 months before randomization.\n\n    iii. Congestive heart failure classified as grade 2 or above by the New York Heart Association (NYHA): Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n\n    iv. Severe cardiac rhythm or conduction abnormalities, including supraventricular or ventricular arrhythmias requiring treatment, QTcF value ≥ 450 ms (males)\u002F≥ 470 ms (females), or second-degree or third-degree atrioventricular block.\n\n    v. History of myocarditis or related examinations suggest active myocarditis. vi. Subjects with heart disease who are assessed by the investigator to be intolerant of other tests.\n19. Patients with a history of interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring corticosteroid therapy, or other pulmonary fibrosis and organising pneumonia that may interfere with the judgment and treatment of immune\u002FSIRT-related pulmonary toxicity.\n20. Patients with severe hemorrhagic tendency or coagulation dysfunction, or receiving thrombolytic therapy; patients who have received or are receiving conventional doses of nonsteroidal anti-inflammatory drugs (such as aspirin, indomethacin ibuprofen and naproxen), antiplatelet drugs (such as clopidogrel, ticlopidine, dipyridamole and cilostazol) or anticoagulants (such as warfarin and low molecular weight heparin) within 10 days before randomization.\n21. Subjects who have participated in other clinical studies and used the investigational drug or device within 30 days before randomization.\n22. Patients with active autoimmune diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids or immunosuppressive agents) within 1 year before randomization or a history of autoimmune diseases that may recur. Patients receiving replacement therapy (such as thyroid hormone replacement therapy for hypothyroidism, type 1 diabetes mellitus requiring only insulin replacement therapy, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) can be enrolled.\n23. Subjects at risk of bleeding, as follows:\n\n    i. Subjects with history of gastrointestinal bleeding or a significant tendency to gastrointestinal bleeding within 6 months before randomization, such as esophageal or gastric variceal bleeding caused by portal hypertension, local active peptic ulcer or persistent faecal occult blood positive.\n\n    ii. Any life-threatening bleeding event within 3 months before randomization, including the events requiring blood transfusion, surgery or local treatment, and continuous drug therapy.\n\n    iii. Subjects with esophageal or gastric varices requiring interventional treatment within 28 days before randomization.\n\n    iv. Untreated or incompletely treated esophageal or gastric fundus varices that are at high risk of bleeding as judged by the investigator.\n24. Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months before randomization.\n25. Patients with intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months before randomization, including incomplete obstruction related to pre-existing diseases or requiring routine parenteral hydration, parenteral nutrition or tube feeding.\n26. History of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism within 3 months before randomization (except for implantable venous access port or catheter-related thrombosis, or superficial vein thrombosis).\n27. Patients who have undergone major surgery or serious trauma within 28 days before randomization (and cannot participate in the study as judged by the investigator); patients with severe unhealed wound, active ulcer or untreated fracture before randomization.\n28. Patients who have received live attenuated vaccine or treatment within 28 days before randomization.\n29. Use of strong CYP3A4 inducers or strong CYP3A4 inhibitors within 7 days before randomization.\n30. Use of immunosuppressive agents or systemic corticosteroids therapy for immunosuppression within 14 days before randomization, excluding topical corticosteroids or systemic application of low-dose prednisone (not more than 10 mg\u002Fday) or equivalent doses of other corticosteroids.\n31. Patients who have received drugs with immunomodulatory effects within 14 days before randomization, including systemic use of thymosin-α1, interferon and interleukin-II.\n32. Pregnant or lactating women, or women who need to continue breastfeeding during the study.\n33. Any other serious diseases, metabolic disorders or laboratory test abnormalities that are not suitable for treatment with the investigational drug, will affect the interpretation of the study results, or put the patient at high risk as judged by the investigator.",{"count":469,"type":21},120,[56],"This study is A Randomized, Active-Controlled, Open-Label National Multicenter Phase 2 Registration Clinical Study of Yttrium \\[90Y\\] Microsphere Injection in Combination with Camrelizumab and\u002For Apatinib and Yttrium \\[90Y\\] Microsphere Injection Alone versus Conventional Transcatheter Arterial Chemoembolization (cTACE) in the Treatment of Unresectable or Non-Ablative, Non-Metastatic Hepatocellular Carcinoma (HCC). Its aim is to evaluate the efficacy and safety of yttrium \\[90Y\\] resin microsphere injection combined with Camrelizumab and\u002For apatinib compared with yttrium \\[90Y\\] resin microsphere injection alone in the treatment of inoperable or ablatable, non-metastatic HCC.",[27],[474],"Yttrium [90Y] Microsphere Injection","2025-12-30",{"date":477,"type":37},"2026-01-12",{"date":479,"type":37},"2025-08-22",{"date":481,"type":21},"2027-12-30",{"name":483,"class":158},"GrandPharma (China) Co., Ltd.",3,{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":495,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":516},"100571259","phase-4-hope-against-cancer-recurrence-in-hcc-100571259","NCT06717919","HOPE Against Cancer Recurrence in HCC","Hypothermic Oxygenated Perfusion (HOPE) Against Cancer Recurrence in HCC Liver Transplantation - International Multicentre Parallel Group Interventional RCT","HOPE4Cancer","Inclusion Criteria:\n\n* Adult recipients (\\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnetic resonance imaging or computer tomography of the liver or biopsy proven),\n* within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point of liver transplantation,\n* written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC\n\nExclusion Criteria:\n\n* Donation after circulatory death (DCD) liver grafts\n* Combined liver transplants\n* Partial liver transplants\n* Combined or mixed hepatocellular cholangiocarcinoma (cHCC-CCC) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant\n* Systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors\n* Post-transplant treatment with mTOR inhibitors\n* Acute and unexpected medical contraindications\n* Pregnancy\n* Cold storage time of \\> 10 hours (both study arms)",{"count":494,"type":21},220,[496],"PHASE4","Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received.\n\nMachine liver perfusion, for example, hypothermic oxygenated liver perfusion (HOPE), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers before implantation. The standard of care is cold storage without perfusion.\n\nThe objective of this study is to compare the survival after tumor recurrence of patients after liver transplantation for HCC between perfused and not perfused livers. This study's hypothesis is that survival without tumor recurrence is improved when the liver is perfused before implantation.\n\nThe study involves transplant centers worldwide, and adults with HCC waiting for liver transplantation are included. 220 Patients will be recruited within 12 months and then observed for at least 2 years after transplantation. To provide the most valid results, the patients will be randomly allocated to either the organ perfusion group or a control group with standard-of-care cold storage of the organ.",[499,27,500],"Liver Transplantation","Oncological Outcomes",[502,503,504,505,506],"HOPE","randomised controlled trial","multicentre","hepatocellular carcinoma","liver transplantation","2025-12-15",{"date":509,"type":37},"2025-12-16",{"date":511,"type":37},"2025-08-01",{"date":513,"type":21},"2028-01-31",{"name":515,"class":44},"Philipp Dutkowski",37,{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":524,"maxAge":166,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":537,"locationsCount":74},"100613869","understanding-gene-environment-interaction-in-alcohol-related-hepatocellular-carcinoma-100613869","NCT07272200","Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma","GENIAL","Inclusion Criteria:\n\nPatients from the EPIDEMIC (approval no. 1822 of 27 August 2013) and SERENA (last amendment no. 1151\\_2021 of 9 November 2021), already approved by the CE Milano Area 2 will be included.\n\n* Diagnosis of NAFLD or cryptogenic liver disease, allowing a more liberal alcohol intake limit (\\\u003C60\u002F40 g\u002Fday in M\u002FF), so that subjects with a moderate alcoholic component of the hepatopathy are also included, Important factor given the high epidemiological weight of this group\n* Any of the following:\n* Male patient with type 2 diabetes or obesity carrying at least three genetic variants in PNPLA3, TM6SF2, MBOAT7.\n* Willingness to sign informed consent.\n\nExclusion Criteria:\n\n* Alcohol intake \\>60\u002F40 g\u002Fday in M\u002FF\n* Chronic viral or autoimmune hepatitis\n* Any previously diagnosed liver genetic disease associated with increased risk of HCC (such as hereditary hemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency)\n* Use of drugs known to induce steatosis and liver disease\n* HCC previously diagnosed the study start date.\n* Other pathological conditions with prognosis less than two years.","45 Years",{"count":526,"type":21},1000,[24],"It has been estimated that alcohol causes around 40% of premature liver deaths in Europe each year, although this number is probably underestimated. Alcohol-related liver disease (ALD) is the most common cause of liver cirrhosis and liver death in Europe with a peak age of deaths occurring among individuals aged 40 to 50. Despite these findings, ALD is little studied with only 5% of all clinical trials in the field of liver disease recorded on ClinicalTrials.gov and only 5% of all publications in the same research area.\n\nLiver cancer is the second most common cause of cancer-related death (15-20% survival at 5 years) and the second most common cause of alcohol-related cancers worldwide.\n\nLike other complex diseases, ALD-HCC results from the interaction between environmental determinants and genetic variations but knowledge of gene-environment interactions is currently lacking in this area. The GENIAL project will address these needs through a comprehensive evaluation of gene-environment interactions concerning ALD-HCC.",[27,530],"Genetic Predisposition","2025-11-26",{"date":533,"type":37},"2025-12-09",{"date":535,"type":37},"2023-12-01",{"date":422,"type":21},{"name":538,"class":44},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":524,"maxAge":166,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":74},"100556290","evaluation-of-risk-of-hepatocellular-carcinoma-100556290","NCT06523179","Evaluation of Risk of hEpatocellular Carcinoma","Study for the Evaluation of Risk of hEpatocellular Carcinoma in NonAlcoholic Fatty Liver","PERSPECTIVE","Inclusion Criteria:\n\n* Diagnosis of NAFLD or cryptogenic liver disease, allowing a more liberal alcohol intake limit (\\\u003C60\u002F40 g\u002Fday in M\u002FF), so as to also include subjects with a moderate alcoholic component of liver disease, an important factor given the high epidemiological burden of this group\n* Age between 45 and 75 years\n* Any of the following criteria:\n* F3-F4 fibrosis, determined histologically, or by non-invasive techniques (stiffness \\> 7.9 kPa at Fibroscan and positivity at the NAFLD fibrosis score or at APRI or at FIB4), or evidence of cirrhosis deriving from biochemical tests or imaging methods;\n* Family history of primary liver cancer in first degree parentage, or carrier status of rare mutations associated with the development of HCC (such as mutations in APOB and TERT)\n* Male patient with type 2 diabetes or obesity carrying at least three genetic variants in PNPLA3, TM6SF2, MBOAT7.\n* Willingness to sign the informed consent.\n\nExclusion Criteria:\n\n* Alcohol intake \\>60\u002F40 g\u002Fday in M\u002FF\n* Chronic viral or autoimmune hepatitis\n* Any previously diagnosed genetic liver disease associated with increased risk of HCC (such as hereditary hemochromatosis, Wilson's disease, Alpha-1 Antitrypsin deficiency)\n* Use of drugs known to induce steatosis and liver disease\n* HCC diagnosed before the study start date.\n* Other pathological conditions with a prognosis of less than two years.",{"count":548,"type":21},500,[24],"Hepatocellular carcinoma (HCC) is the fifth most common solid cancer and the second cause of cancer-related mortality worldwide. Nonalcoholic fatty liver disease (NAFLD), that is hepatic accumulation of fat in excess of 5% not explained by at risk alcohol intake, is projected to become the leading cause of HCC in Western countries within 2025.NAFLD is most frequently caused by insulin resistance due to unhealthy lifestyle. Due to the epidemics of obesity and type 2 diabetes, NAFLD now affects one in three individuals worldwide.\n\nNAFLD-HCC frequently develops without overt cirrhosis suggesting that steatosis directly promotes hepatic carcinogenesis.",[552,27,530],"NASH","2025-11-17",{"date":555,"type":37},"2025-11-20",{"date":557,"type":37},"2018-01-01",{"date":559,"type":21},"2035-12-31",{"name":538,"class":44},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":569,"sex":17,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":578,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100605910","phase-2-partial-immune-boost-tace-in-unresectable-hcc-patients-under-systemic-treatment-100605910","NCT07168668","Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment","Exploring Clinical Efficacy of Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment (EXEPECT Trial)","EXEPECT","inclusion criteria:\n\n1. Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of \\\u003C 20 cm, and no one lesion \\> 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:\n\n   Histologically or cytologically proven diagnosis of HCC. Typical arterial enhancement and delayed washout on multiphasic CT or MRI.\n2. Age ≥18 years at the time of signing informed consent document.\n3. ECOG performance status 0-1.\n4. Barcelona Clinic Liver Cancer (BCLC) stages B or C.\n5. Child-Pugh score 5-6 liver function within 28 days of study registration.\n6. Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.\n7. Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.\n8. Ability to understand and the willingness to sign a written informed consent document\n9. Adequate bone marrow, liver, and renal function within 4 weeks before study registration\n\n   * Hemoglobin ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   * Platelet count ≥ 50,000\u002FμL\n   * Total bilirubin \\\u003C 2.5 mg\u002FdL\n   * Serum albumin \\>2.8 g\u002FdL\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)\n   * Prothrombin time ≤ 6 seconds prolonged\n   * Serum creatinine ≤ 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n1. Prior invasive malignancy unless disease free for a minimum of 2 years\n2. Prior radiotherapy to the region of the liver that would result in overlap of embolization fields\n3. Prior selective internal radiotherapy\u002Fhepatic arterial yttrium therapy, at any time\n4. Untreated active hepatitis B or hepatitis C\n5. Moderate to severe or intractable ascites\n6. Untreated or incomplete treated esophageal or gastric varices\n7. Severe, active co-morbidity, defined as follows:\n\n   * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months prior to registration\n   * Myocardial infarction within the last 6 months prior to study entry\n   * Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry\n   * A bleeding episode within 6 months prior to study entry due to any cause. o Thrombolytic therapy within 28 days prior to study entry.\n   * Known bleeding or clotting disorder.\n   * Uncontrolled psychotic disorder\n8. Pregnancy or women of childbearing potential and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n9. Prior solid organ transplantation.\n10. Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.\n11. Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.\n12. Known HIV infection.",true,"20 Years",{"count":572,"type":21},90,[56],"Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4; anti-CTLA4) have recently been established as a standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). However, its objective response rate (ORR) is only less than 27% (1, 2), and the majority of patients died of HCC progression and liver failure. Therefore, there is an urgent need to develop a novel combination treatment strategy to overcome resistance to immunotherapy and improve patient outcomes.\n\nTransarterial chemoembolization (TACE) remains the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) (3, 4). However, in our previous retrospective study (5-7), the investigators consistently observed that this combination not only improves therapeutic responses but also significantly prolongs patient survival. The tumor necrosis caused by TACE may enhance the efficacy of systemic therapies by promoting the release of neoantigens, thereby stimulating immune responses (8-14). This concept has been substantiated in two recent trials involving intermediate-stage HCC (15, 16), where the addition of immune checkpoint inhibitors to TACE resulted in improved clinical outcomes. Nevertheless, this promising approach has yet to replace the decades-old standard treatment protocols, underscoring the need for further proof-of-concept studies.\n\nBoth immunotherapy (atezolizumab\u002Fbevacizumab or durvalumab\u002Ftremelimumab) and transarterial chemoembolization (TACE) are approved treatment modalities for unresectable hepatocellular carcinoma (HCC) by the U.S. and Taiwan Food and Drug Administration (FDA). This phase II non-randomized trial is designed to prospectively evaluate the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with a combination of immunotherapy and TACE. A particular focus of this study is to explore the potential immune-boosting effects of TACE, including its ability to enhance antigen presentation and stimulate anti-tumor immune responses.",[27,576,577],"Tace","Immunotherapy",[579,64,580],"hepatocelluar carcinoma","immunotherapy","2025-09-04",{"date":120,"type":37},{"date":584,"type":21},"2025-09-15",{"date":586,"type":21},"2028-05-30",{"name":588,"class":44},"Chang Gung Memorial Hospital",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":598,"briefSummary":599,"conditions":600,"keywords":601,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":607,"leadSponsor":609,"locationsCount":74},"100600575","phase-2-lparomlimab-and-tuvonralimab-injection-in-combination-with-tace-and-lenvatinib-in-the-treatment-of-second-line-therapy-for-unresectable-intermediate-to-advanced-hepatocellular-carcinoma-100600575","NCT07099274","Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma","A Single-Arm, Single-Center Clinical Study Evaluating the Efficacy and Safety of Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib as Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Comprehension and voluntary signing of the study's informed consent form;\n* Age ≥18 years, any gender;\n* Histologically or clinically confirmed hepatocellular carcinoma;\n* Documented failure or intolerance to first-line therapy with PD-1\u002FPD-L1 inhibitor plus bevacizumab;\n* ECOG performance status 0-2;\n* Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;\n* Life expectancy ≥3 months;\n* At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;\n* Adequate organ and bone marrow function within 7 days prior to initial study treatment;\n* Active HBV\u002FHCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.\n\n  2.Exclusion Criteria:\n* Inability to comply with the study protocol or procedures;\n* Histologically\u002Fcytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;\n* History of liver transplantation or planned transplantation;\n* Presence of central nervous system metastases and\u002For leptomeningeal carcinomatosis;\n* Baseline imaging showing Vp4 portal vein tumor thrombosis;\n* Hypersensitivity to any study drug components or history of severe allergic reactions;\n* Concurrent HBV and HCV co-infection;\n* Clinically significant ascites requiring intervention during screening;\n* Concurrent use of other investigational drugs or participation in another clinical trial within 4 weeks prior to enrollment;\n* Esophageal\u002Fgastric variceal bleeding due to portal hypertension within 6 months before treatment initiation, or high-risk varices on endoscopy within 3 months;\n* Current interstitial lung disease (ILD), history of steroid-required ILD, or other pulmonary fibrosis\u002Forganizing pneumonia affecting immune-related pulmonary toxicity assessment;\n* Uncontrolled hypertension (SBP≥160 mmHg and\u002For DBP≥100 mmHg despite medication), coronary artery disease, arrhythmias, or heart failure (NYHA Class ≥II);\n* Uncontrolled clinically significant infections requiring IV antimicrobial therapy;\n* Proteinuria ≥2+ (≥1.0g\u002F24h);\n* History of hemorrhagic tendency regardless of severity within 2 months prior to enrollment;\n* Arterial\u002Fvenous thromboembolic events within 12 months before treatment initiation (e.g., cerebrovascular accident including TIA);\n* Acute myocardial infarction, acute coronary syndrome, or CABG within 6 months before treatment;\n* Unhealed fractures or chronic non-healing wounds;\n* Coagulopathy, bleeding diathesis, or current therapeutic anticoagulation;\n* Other malignancies within 5 years except curatively resected basal\u002Fsquamous cell skin carcinoma or cervical carcinoma in situ;\n* Active autoimmune disease or autoimmune disease history requiring immunosuppression within 4 weeks prior to enrollment;\n* Prior allogeneic bone marrow or solid organ transplantation;\n* Investigator assessment of ineligibility based on medical\u002Fsafety reasons.",{"count":597,"type":21},29,[56],"Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1\u002F CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable intermediate-to-advanced hepatocellular carcinoma.",[27],[602,63,603],"Iparomlimab and Tuvonralimab Injection","Lenvatinib",{"date":605,"type":37},"2025-08-29",{"date":479,"type":37},{"date":608,"type":21},"2029-12-30",{"name":610,"class":44},"Tianjin Medical University Cancer Institute and Hospital",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":22,"phases":620,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":4},"100602163","phase-2-a-clinical-study-evaluating-haic-combined-with-iparomlimab-and-tuvonralimab-injection-plus-bevacizumab-in-patients-with-initially-potentially-resectable-hepatocellular-carcinoma-itbhaic-study-100602163","NCT07119931","A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)","A Single-Arm, Single-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)","Inclusion Criteria:\n\n1. Subjects voluntarily join this study, sign the informed consent form, and demonstrate good compliance;\n2. Age ≥ 18 years, regardless of gender;\n3. HCC confirmed histologically\u002Fcytologically or meeting the clinical diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition), with no evidence of extrahepatic metastasis;\n4. Potentially resectable HCC must meet ALL of the following criteria:\n\n   a. Deemed unsuitable for primary surgical resection at the current stage by the Multidisciplinary Team (MDT) assessment at the research center; b. At least one untreated measurable lesion according to RECIST v1.1 criteria. (Note: Subjects who received prior local therapy for non-target lesions are eligible. Local therapy must have been completed at least 4 weeks prior to baseline scans.); c. Largest tumor diameter ≥5 cm AND ≤3 tumor lesions; d. Absence of Vp3-Vp4 stage portal vein tumor thrombus (PVTT) as per the Japanese PVTT classification system; e. Oligometastasis is permitted;\n5. No prior systemic therapy for HCC (including investigational systemic agents);\n6. Child-Pugh score class A or well-compensated class B (score ≤7);\n7. Subjects with HBV or HCV infection must meet the following criteria:\n\n1\\) HBV-infected subjects (HBsAg positive or HBV-DNA positive): Must have received guideline-recommended antiviral therapy for at least 3 days prior to the first study treatment, demonstrating a decreasing trend in HBV-DNA levels. Must continue to receive standard antiviral therapy throughout the study period; 2) HCV-infected subjects (HCVAb positive or HCV RNA positive): Must be in a stable condition per investigator assessment. If receiving antiviral therapy, must continue treatment throughout the study period; 3) Co-infection with HBV and HCV is not allowed. (Note: A history of HCV infection with undetectable HCV-RNA is considered absence of current HCV infection); 8.ECOG Performance Status score of 0-1 (Appendix 1); 9.Life expectancy ≥3 months; 10.Adequate organ function within 7 days prior to treatment, meeting all the following criteria: Hemoglobin (Hb) ≥90 g\u002FL; White blood cell count (WBC) ≥3.5 × 10⁹\u002FL; Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL; Platelet count (PLT) ≥75 × 10⁹\u002FL; AST and ALT ≤5 × upper limit of normal (ULN); Total bilirubin ≤3 × ULN; Serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance (CrCl) ≥40 mL\u002Fmin (Appendix 2); Urinalysis showing urine protein \\\u003C2+(For subjects with baseline urinalysis showing urine protein ≥2+, a 24-hour urine collection must demonstrate 24-hour urine protein \\\u003C1 g); Adequate coagulation function, defined as: International Normalized Ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 × ULN; Normal thyroid function, defined as: Thyroid-stimulating hormone (TSH) within normal range. (Subjects with baseline TSH outside normal range may enroll if free triiodothyronine (FT3) or total T3 and free thyroxine (FT4) are within normal limits); 11.Male subjects and subjects of childbearing potential must use highly effective contraception from informed consent signing until 6 months after last study treatment. Subjects of childbearing potential must have a negative pregnancy test within 7 days prior to first treatment.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Histologically\u002Fcytologically confirmed HCC containing fibrolamellar, sarcomatoid, or cholangiocarcinoma components;\n3. History of other primary malignancies within 5 years (except adequately treated and stable non-melanoma skin cancer, basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix);\n4. Current or prior central nervous system (CNS) metastases or leptomeningeal metastasis;\n5. Bleeding tendency, high bleeding risk, or coagulation dysfunction: including but not limited to thromboembolic events (e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism) within 6 months prior to screening; and\u002For history of hemoptysis (≥2.5 ml bright red blood per episode) within 3 months prior to screening; current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for treatment; significant risk of gastrointestinal bleeding as judged by the investigator;\n6. Presence of unhealed fractures, wound dehiscence requiring intervention, wound healing complications; tracheoesophageal fistula, gastrointestinal perforation or fistula, or intra-abdominal abscess within 6 months prior to screening;\n7. Major surgery within 4 weeks before first dose (defined as Grade III or higher surgical procedures, excluding central venous catheter placement, tumor biopsy, etc.) or significant trauma with incomplete recovery;\n8. Significant cardiovascular diseases (e.g., NYHA Class II or higher heart failure, myocardial infarction, or cerebrovascular events within 3 months before initiating study treatment), unstable arrhythmias, or unstable angina;\n9. Active autoimmune diseases or history of autoimmune disorders including but not limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis, hypophysitis, vasculitis, systemic lupus erythematosus; Note: Excludes hypothyroidism stabilized with physiologic hormone replacement, type I diabetes controlled with stable insulin therapy, or autoimmune thyroiditis managed with stable hormone replacement.\n10. Diagnosed immunodeficiency or anticipated need for systemic immunosuppressive therapy during study treatment, or prior use of systemic corticosteroids\u002Fimmunosuppressants before first treatment; Note: Excludes topical\u002Fnasal\u002Finhaled corticosteroids, physiologic systemic corticosteroids (≤10 mg\u002Fday prednisone equivalents), and transient corticosteroid use for COPD\u002Fasthma\u002Fallergy prophylaxis;\n11. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia on screening chest CT scan;\n12. Severe infection within 4 weeks before initiating study treatment, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective therapy within 2 weeks before first dose (excluding antiviral therapy for HBV\u002FHCV);\n13. Poorly controlled comorbidities despite optimal management before first treatment: Uncontrolled hyperglycemia (defined as fasting blood glucose ≥7 mmol\u002FL, unstable oral hypoglycemic regimen, or unstable glycemic control per specialist assessment); Uncontrolled hypertension (SBP \\>150 mmHg and\u002For DBP \\>100 mmHg after ≥2 antihypertensive agents) or history of hypertensive crisis\u002Fencephalopathy; Refractory malignant pleural effusion, ascites, or pericardial effusion (defined as symptomatic re-accumulation requiring re-intervention within 2 weeks after drainage);\n14. Known hypersensitivity to the investigational drug or its excipients;\n15. Any other severe\u002Funcontrolled comorbidity that may compromise safety or efficacy assessments per investigator judgment (e.g., hepatic encephalopathy, uncorrectable coagulopathy, hepatorenal syndrome, or cachexia).",{"count":619,"type":21},34,[56],"Major Objectives To evaluate the efficacy of HAIC combined with Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1\u002FCTLA-4 Combined Antibody) plus bevacizumab as a conversion therapy in patients with potentially resectable HCC, assessed by the conversion resection rate.",[27],[624,625,626],"lparomlimab and Tuvonralimab Injection","HAIC","bevacizumab","2025-08-06",{"date":629,"type":37},"2025-08-13",{"date":631,"type":21},"2025-09-10",{"date":608,"type":21},{"name":610,"class":44},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":641,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":656},"100593503","real-world-study-on-liver-cancer-risk-in-chronic-hepatitis-b-patients-with-family-history-of-liver-cancer-100593503","NCT07007286","Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer","A Real-World Study on Reducing the Risk of Liver Cancer in Chronic Hepatitis B Patients With a Family History of HBV-Related Liver Cancer.","Inclusion Criteria:\n\n* (1) Chronic hepatitis B (CHB) patients with HBsAg positivity for over 6 months; (2) Family history of HBV-related hepatocellular carcinoma (HCC) (first- or second-degree relatives with HBV-related HCC); (3) Age ≥ 30 years, regardless of gender; (4) Based on real-world clinical practice, patients receiving nucleos(t)ide analogue (NA) therapy, such as Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide Fumarate (TAF), or Tenofovir Amibufenamide (TMF), or those receiving combination therapy with nucleos(t)ide analogues and PEG IFNα-2b; (5) Negative pregnancy test within 24 hours before the first dose (for women of childbearing potential); (6) Voluntary participation, with the ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Patients diagnosed with hepatocellular carcinoma (HCC) or malignancies in other organ systems prior to treatment; (2) Patients with contraindications to Peg IFN α-2b (refer to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition) for details); (3) Patients in the immune-tolerant phase of HBV infection; (4) Patients scheduled for or with a history of organ transplantation; (5) Patients with hypersensitivity to interferon or any contraindication listed in the drug's prescribing information; (6) Other conditions deemed unsuitable for enrollment by the investigator.","30 Years",{"count":643,"type":21},1500,"This study is a prospective, multicenter, real-world cohort study designed to compare the long-term outcomes of chronic hepatitis B patients with a family history of HBV-related hepatocellular carcinoma (HCC) who receive PEG IFNα-2b combined with nucleos(t)ide analogues or nucleos(t)ide monotherapy. The primary endpoint is the incidence rate of HCC, and secondary endpoints include the rate of HBsAg seroclearance, changes in liver fibrosis, and survival rates. The study will last for 5 years and enroll approximately 15,000 patients, aiming to provide evidence-based optimization for CHB treatment regimens.",[646,27],"HBV","2025-05-28",{"date":649,"type":37},"2025-06-05",{"date":651,"type":21},"2025-06",{"date":653,"type":21},"2032-12",{"name":655,"class":44},"Peking University First Hospital",555]